Evidence map›Paper›PMID 40290933›Full record

ArticleACS omega2025

Assessing the Robustness and Scalability of Machine Learning Methods to Accelerate Ultralarge High-Throughput Docking Campaigns.

Juan I Di Filippo, Santiago Rómoli, Claudio N Cavasotto

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Juan I Di FilippoComputational Drug Design and Biomedical Informatics Laboratory, Instituto de Investigaciones en Medicina Traslacional (IIMT), CONICET-Universidad Austral, Pilar, Buenos Aires 1629, Argentina.
Santiago RómoliComputational Drug Design and Biomedical Informatics Laboratory, Instituto de Investigaciones en Medicina Traslacional (IIMT), CONICET-Universidad Austral, Pilar, Buenos Aires 1629, Argentina.
Claudio N CavasottoComputational Drug Design and Biomedical Informatics Laboratory, Instituto de Investigaciones en Medicina Traslacional (IIMT), CONICET-Universidad Austral, Pilar, Buenos Aires 1629, Argentina.ORCID https://orcid.org/0000-0002-1372-0379

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structure-based virtual screening methods are, nowadays, one of the key pillars of computational drug discovery. In recent years, high-throughput docking campaigns aided by machine learning (ML)-based protocols have emerged as a way to accelerate the identification of top-scoring molecules within ultralarge chemical molecule libraries. However, studies validating these ML approaches used one or two targets and/or small molecule libraries. Herein, we extended the validation of ML protocols at retrieving virtual hits in an accelerated fashion by using two standard publicly available ∼100M molecule libraries and also a comprehensive benchmark set involving molecular docking scores of a 10M molecule library in 10 diverse protein targets with two docking programs, PLANTS and AutoDock Vina. In the 10M benchmark set, we have shown that, on average, more than 60 and 70% of the top 10k and top 1k molecules, respectively, can be retrieved while reducing the number of docking evaluations by more than 97%, indicating a robust performance of the ML protocol. With larger molecule libraries, we have shown that a proportional increase in the training set size enhances the performance of the ML model at retrieving virtual hits. In summary, our results support the use of ML methods to retrieve top-scoring molecules for chemical libraries containing hundreds of millions or even billions of molecules, where the role of ML models becomes even more critical as brute-force exploration of such chemical libraries through molecular docking is inaccessible in reasonable time frames.

Identifiers

PMID40290933
PMCPMC12019444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.